{"id":1179,"date":"2023-09-22T22:52:05","date_gmt":"2023-09-22T22:52:05","guid":{"rendered":"https:\/\/oncologytweetorials-ce.com\/?p=1179"},"modified":"2023-09-25T12:51:04","modified_gmt":"2023-09-25T12:51:04","slug":"cat3","status":"publish","type":"post","link":"https:\/\/oncologytweetorials-ce.com\/cat3\/","title":{"rendered":"Current Data and Guidelines for Safe and Well-Managed Anticoagulation in Cancer-Associated Thrombosis"},"content":{"rendered":"\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">1b) Our expert co-faculty are Tzu-Fei Wang MD <a href=\"https:\/\/twitter.com\/TzufeiWang?ref_src=twsrc%5Etfw\">@TzufeiWang<\/a>, <a href=\"https:\/\/twitter.com\/hashtag\/thrombosis?src=hash&amp;ref_src=twsrc%5Etfw\">#thrombosis<\/a> &amp; benign <a href=\"https:\/\/twitter.com\/hashtag\/shematologist?src=hash&amp;ref_src=twsrc%5Etfw\">#shematologist<\/a> from <a href=\"https:\/\/twitter.com\/OttawaHospital?ref_src=twsrc%5Etfw\">@OttawaHospital<\/a> and founding <a href=\"https:\/\/twitter.com\/onc_ce?ref_src=twsrc%5Etfw\">@onc_ce<\/a> faculty Alok Khorana MD <a href=\"https:\/\/twitter.com\/aakonc?ref_src=twsrc%5Etfw\">@aakonc<\/a>, Hardis Endowed Chair, Prof Med, Vice Chair Taussig Cancer Inst, Dir GI Cancers, <a href=\"https:\/\/twitter.com\/ClevelandClinic?ref_src=twsrc%5Etfw\">@ClevelandClinic<\/a> <a href=\"https:\/\/t.co\/jKzhDBw1Ly\">pic.twitter.com\/jKzhDBw1Ly<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268572970844435?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">3) Let&#39;s start with the basics. Patients with <a href=\"https:\/\/twitter.com\/hashtag\/cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#cancer<\/a> have a 12X increased risk of VTE compared to those without cancer, with the risk further increased to 23X with <a href=\"https:\/\/twitter.com\/hashtag\/anticancer?src=hash&amp;ref_src=twsrc%5Etfw\">#anticancer<\/a> therapy.<br>\ud83d\udd13 <a href=\"https:\/\/t.co\/4sgmgoVNkn\">https:\/\/t.co\/4sgmgoVNkn<\/a> <a href=\"https:\/\/t.co\/jesSuUnuvz\">pic.twitter.com\/jesSuUnuvz<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268576770822598?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">5) In 2003, <a href=\"https:\/\/twitter.com\/hashtag\/CLOT?src=hash&amp;ref_src=twsrc%5Etfw\">#CLOT<\/a> was the first pivotal <a href=\"https:\/\/twitter.com\/hashtag\/RCT?src=hash&amp;ref_src=twsrc%5Etfw\">#RCT<\/a> in <a href=\"https:\/\/twitter.com\/hashtag\/CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#CAT<\/a> to show that <a href=\"https:\/\/twitter.com\/hashtag\/LMWH?src=hash&amp;ref_src=twsrc%5Etfw\">#LMWH<\/a> is superior to <a href=\"https:\/\/twitter.com\/hashtag\/VKA?src=hash&amp;ref_src=twsrc%5Etfw\">#VKA<\/a> in preventing recurrent VTE without an increased risk of bleeding \ud83e\ude78.<br>\ud83d\udd13 <a href=\"https:\/\/t.co\/THDX0NfdNk\">https:\/\/t.co\/THDX0NfdNk<\/a> <a href=\"https:\/\/t.co\/Db5AkfGAFu\">pic.twitter.com\/Db5AkfGAFu<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268580541608165?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">6b) <a href=\"https:\/\/t.co\/90Mx2L6wHl\">https:\/\/t.co\/90Mx2L6wHl<\/a><br>Safety: <a href=\"https:\/\/t.co\/HOVuJ4ILiT\">pic.twitter.com\/HOVuJ4ILiT<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268584412942428?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">8)<br>\ud83d\udc49<a href=\"https:\/\/twitter.com\/hashtag\/Select_D?src=hash&amp;ref_src=twsrc%5Etfw\">#Select_D<\/a> trial (N=406) <a href=\"https:\/\/t.co\/e4PZsERVST\">https:\/\/t.co\/e4PZsERVST<\/a><br>\ud83d\udc49<a href=\"https:\/\/twitter.com\/hashtag\/CASTA_DIVA?src=hash&amp;ref_src=twsrc%5Etfw\">#CASTA_DIVA<\/a> trial (N=158) <a href=\"https:\/\/t.co\/oh9bDffHQX\">https:\/\/t.co\/oh9bDffHQX<\/a><br>These compared <a href=\"https:\/\/twitter.com\/hashtag\/rivaroxaban?src=hash&amp;ref_src=twsrc%5Etfw\">#rivaroxaban<\/a> to <a href=\"https:\/\/twitter.com\/hashtag\/dalteparin?src=hash&amp;ref_src=twsrc%5Etfw\">#dalteparin<\/a>. Rivaroxaban was associated with an increased risk of <a href=\"https:\/\/twitter.com\/hashtag\/CRNMB?src=hash&amp;ref_src=twsrc%5Etfw\">#CRNMB<\/a> in Select-D. <a href=\"https:\/\/t.co\/rlcMVKt3rP\">pic.twitter.com\/rlcMVKt3rP<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268588883976278?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">10) Same comparison, similar results in <a href=\"https:\/\/twitter.com\/hashtag\/ADAM_VTE?src=hash&amp;ref_src=twsrc%5Etfw\">#ADAM_VTE<\/a> trial (N=300)<br>\ud83d\udd13 <a href=\"https:\/\/t.co\/djVKk1mTZq\">https:\/\/t.co\/djVKk1mTZq<\/a> <a href=\"https:\/\/t.co\/XSVGI1m50k\">pic.twitter.com\/XSVGI1m50k<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268593111920840?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">12a) So where are we?<br>\ud83d\udc49Major international guidelines rec <a href=\"https:\/\/twitter.com\/hashtag\/DOACs?src=hash&amp;ref_src=twsrc%5Etfw\">#DOACs<\/a> or <a href=\"https:\/\/twitter.com\/hashtag\/LMWH?src=hash&amp;ref_src=twsrc%5Etfw\">#LMWH<\/a> as anticoagulants of choice for <a href=\"https:\/\/twitter.com\/hashtag\/CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#CAT<\/a>.<br>\ud83d\udc49DOACs might be preferred except for pts at \u2b06\ufe0frisk of \ud83e\ude78(such as unresected luminal GI and GU <a href=\"https:\/\/twitter.com\/hashtag\/cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#cancer<\/a>) or with clinically important drug-drug interactions <a href=\"https:\/\/twitter.com\/hashtag\/DDIs?src=hash&amp;ref_src=twsrc%5Etfw\">#DDIs<\/a>. <a href=\"https:\/\/t.co\/Oo6OfafzJm\">pic.twitter.com\/Oo6OfafzJm<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268596962279430?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">13) In patients with well-managed <a href=\"https:\/\/twitter.com\/hashtag\/CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#CAT<\/a> and active <a href=\"https:\/\/twitter.com\/hashtag\/cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#cancer<\/a>, how should we treat after 6 months of <a href=\"https:\/\/twitter.com\/hashtag\/anticoagulation?src=hash&amp;ref_src=twsrc%5Etfw\">#anticoagulation<\/a>?<br>\ud83d\udc49<a href=\"https:\/\/twitter.com\/hashtag\/Guidelines?src=hash&amp;ref_src=twsrc%5Etfw\">#Guidelines<\/a> rec continued anticoagulants as long as cancer is active, but full vs reduced dose of anticoagulation is debatable. <a href=\"https:\/\/t.co\/mMx2pkxMKZ\">pic.twitter.com\/mMx2pkxMKZ<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268618856493176?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">14b) Results <a href=\"https:\/\/twitter.com\/hashtag\/EVE?src=hash&amp;ref_src=twsrc%5Etfw\">#EVE<\/a>, apixaban 2.5mg BID vs 5mg BID:<br>\ud83d\udc4912mo risk of MB+CRNMB: 8.9% vs 12.2%, HR 0.72, 95% CI 0.38-1.37<br>\ud83d\udc4912mo risk of recurrent VTE: 5.0% vs 4.4%, HR 1.00, 95% CI 0.40 \u2013 2.53)<br>Small study but encouraging results <a href=\"https:\/\/t.co\/JdtVGyLXlF\">pic.twitter.com\/JdtVGyLXlF<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268623453450443?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">15b) <a href=\"https:\/\/twitter.com\/hashtag\/API_CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#API_CAT<\/a> is an international, randomized, parallel-group, double-blind, noninferiority trial with blinded adjudication of outcome events. Consecutive patients are randomized to receive <a href=\"https:\/\/twitter.com\/hashtag\/apixaban?src=hash&amp;ref_src=twsrc%5Etfw\">#apixaban<\/a> 2.5 or 5 mg bid for 12 months.<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268627417043189?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">16a) That is likely the top of the \ud83d\uddfbfor <a href=\"https:\/\/twitter.com\/hashtag\/DOACs?src=hash&amp;ref_src=twsrc%5Etfw\">#DOACs<\/a> in <a href=\"https:\/\/twitter.com\/hashtag\/CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#CAT<\/a>. Problem is, many pts with active <a href=\"https:\/\/twitter.com\/hashtag\/cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#cancer<\/a> aren&#39;t well-suited for <a href=\"https:\/\/twitter.com\/hashtag\/DOACs?src=hash&amp;ref_src=twsrc%5Etfw\">#DOACs<\/a> because \u2b06\ufe0f risk of \ud83e\ude78 bleeding (especially unresected GI and GU <a href=\"https:\/\/twitter.com\/hashtag\/cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#cancer<\/a>) or with clinically important drug-to-drug interactions (<a href=\"https:\/\/twitter.com\/hashtag\/DDIs?src=hash&amp;ref_src=twsrc%5Etfw\">#DDIs<\/a>).<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268630554456249?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">17a) Factor XI (<a href=\"https:\/\/twitter.com\/hashtag\/FXI?src=hash&amp;ref_src=twsrc%5Etfw\">#FXI<\/a>) inhibitors have the potential to be safer than DOACs<br>\ud83d\udc49\u2b06\ufe0fFXI levels are associated with \u2b06\ufe0f risk of <a href=\"https:\/\/twitter.com\/hashtag\/VTE?src=hash&amp;ref_src=twsrc%5Etfw\">#VTE<\/a>.<br>\ud83d\udc49Congenital FXI deficiency is not associated with \u2b06\ufe0f risk of \ud83e\ude78<br>\ud83d\udd11 FXI may be an attractive target for <a href=\"https:\/\/twitter.com\/hashtag\/CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#CAT<\/a>.<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706268633712742693?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">18a) 4\u20e3 FXI inhibitors are currently being investigated for different indications: 1\u20e3 antisense oligonucleotide <a href=\"https:\/\/twitter.com\/hashtag\/ASO?src=hash&amp;ref_src=twsrc%5Etfw\">#ASO<\/a> (<a href=\"https:\/\/twitter.com\/hashtag\/fesomersen?src=hash&amp;ref_src=twsrc%5Etfw\">#fesomersen<\/a>); 2\u20e3 monoclonal antibodies <a href=\"https:\/\/twitter.com\/hashtag\/MAbs?src=hash&amp;ref_src=twsrc%5Etfw\">#MAbs<\/a> (<a href=\"https:\/\/twitter.com\/hashtag\/abelacimab?src=hash&amp;ref_src=twsrc%5Etfw\">#abelacimab<\/a> and <a href=\"https:\/\/twitter.com\/hashtag\/osocimab?src=hash&amp;ref_src=twsrc%5Etfw\">#osocimab<\/a>); and 2\u20e3 small molecules (<a href=\"https:\/\/twitter.com\/hashtag\/milvexian?src=hash&amp;ref_src=twsrc%5Etfw\">#milvexian<\/a> and <a href=\"https:\/\/twitter.com\/hashtag\/asundexian?src=hash&amp;ref_src=twsrc%5Etfw\">#asundexian<\/a>).<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706270123361697952?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">19) Abelacimab is a humanized monoclonal antibody that binds FXI and prevents its activation by FXIIa and thrombin. Parenteral administration \ud83d\udc89 + rapid and dose dependent FXI inhibition + Half-life: 2\u20e30\u20e3 days.<a href=\"https:\/\/t.co\/COWrA6Nvxs\">https:\/\/t.co\/COWrA6Nvxs<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706270126226465097?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">21) 2\u20e3 RCTs, comparator-controlled, are assessing the efficacy &amp; safety of <a href=\"https:\/\/twitter.com\/hashtag\/abelacimab?src=hash&amp;ref_src=twsrc%5Etfw\">#abelacimab<\/a> for the management of <a href=\"https:\/\/twitter.com\/hashtag\/CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#CAT<\/a>.<br>\ud83d\udc49<a href=\"https:\/\/twitter.com\/hashtag\/ASTER?src=hash&amp;ref_src=twsrc%5Etfw\">#ASTER<\/a> (NCT 05171049): Abelacimab vs. apixaban<br>\ud83d\udc49<a href=\"https:\/\/twitter.com\/hashtag\/MAGNOLIA?src=hash&amp;ref_src=twsrc%5Etfw\">#MAGNOLIA<\/a> (NCT 05171075): Abelacimab vs. <a href=\"https:\/\/twitter.com\/hashtag\/LMWH?src=hash&amp;ref_src=twsrc%5Etfw\">#LMWH<\/a> (<a href=\"https:\/\/twitter.com\/hashtag\/dalteparin?src=hash&amp;ref_src=twsrc%5Etfw\">#dalteparin<\/a>) in patients with GI and GU tumors<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706270129237979291?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">23) Potential challenges with <a href=\"https:\/\/twitter.com\/hashtag\/abelacimab?src=hash&amp;ref_src=twsrc%5Etfw\">#abelacimab<\/a> in patients with <a href=\"https:\/\/twitter.com\/hashtag\/cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#cancer<\/a><br>\ud83d\udc49Management of bleeding episodes (antifibrinolytic agents? low dose FVIIa?)<br>\ud83d\udc49Management of recurrent <a href=\"https:\/\/twitter.com\/hashtag\/VTE?src=hash&amp;ref_src=twsrc%5Etfw\">#VTE<\/a><br>\ud83d\udc49Management of thrombocytopenia<br>\ud83d\udc49Peri-operative management<br>\ud83d\udea8 Stay tuned!<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706270132060778739?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">24b) It&#39;s b, a <a href=\"https:\/\/twitter.com\/hashtag\/LMWH?src=hash&amp;ref_src=twsrc%5Etfw\">#LMWH<\/a>, and <a href=\"https:\/\/twitter.com\/hashtag\/dalteparin?src=hash&amp;ref_src=twsrc%5Etfw\">#dalteparin<\/a> is most often used in clinical trials. These patients have among the highest \ud83e\ude78risk in the <a href=\"https:\/\/twitter.com\/hashtag\/CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#CAT<\/a> world.<br>Now, which of the following IS NOT a remaining unmet need for the management of <a href=\"https:\/\/twitter.com\/hashtag\/CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#CAT<\/a>?<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706270136217341961?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">25) You just earned 0.5hr \ud83c\udd93CE\/<a href=\"https:\/\/twitter.com\/hashtag\/CME?src=hash&amp;ref_src=twsrc%5Etfw\">#CME<\/a>! Grab your certificate for credit at <a href=\"https:\/\/t.co\/M4PS9tVLjQ\">https:\/\/t.co\/M4PS9tVLjQ<\/a>, and follow us here on <a href=\"https:\/\/twitter.com\/onc_ce?ref_src=twsrc%5Etfw\">@onc_ce<\/a> for more education on this &amp; other topics related to <a href=\"https:\/\/twitter.com\/hashtag\/cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#cancer<\/a>, <a href=\"https:\/\/twitter.com\/hashtag\/CAT?src=hash&amp;ref_src=twsrc%5Etfw\">#CAT<\/a>, <a href=\"https:\/\/twitter.com\/hashtag\/Cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#Cancer<\/a> &amp; <a href=\"https:\/\/twitter.com\/hashtag\/VTE?src=hash&amp;ref_src=twsrc%5Etfw\">#VTE<\/a>! <a href=\"https:\/\/twitter.com\/TzufeiWang?ref_src=twsrc%5Etfw\">@TzufeiWang<\/a> &amp; <a href=\"https:\/\/twitter.com\/aakonc?ref_src=twsrc%5Etfw\">@aakonc<\/a> thank you for joining us!<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1706270139140718692?ref_src=twsrc%5Etfw\">September 25, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<iframe\n      id=\"JotFormIFrame-232647399171162\"\n      title=\"CAT3 | Oncology CE 2023new\"\n      onload=\"window.parent.scrollTo(0,0)\"\n      allowtransparency=\"true\"\n      allowfullscreen=\"true\"\n      allow=\"geolocation; microphone; camera\"\n      src=\"https:\/\/form.jotform.com\/232647399171162\"\n      frameborder=\"0\"\n      style=\"min-width:100%;max-width:100%;height:1539px;border:none;\"\n      scrolling=\"no\"\n    >\n    <\/iframe>\n    <script type=\"text\/javascript\">\n    var ifr = document.getElementById(\"JotFormIFrame-232647399171162\");\n    if (ifr) {\n      var src = ifr.src;\n      var iframeParams = [];\n      if (window.location.href && window.location.href.indexOf(\"?\") > -1) {\n        iframeParams = iframeParams.concat(window.location.href.substr(window.location.href.indexOf(\"?\") + 1).split('&'));\n      }\n      if (src && src.indexOf(\"?\") > -1) {\n        iframeParams = iframeParams.concat(src.substr(src.indexOf(\"?\") + 1).split(\"&\"));\n        src = src.substr(0, src.indexOf(\"?\"))\n      }\n      iframeParams.push(\"isIframeEmbed=1\");\n      ifr.src = src + \"?\" + iframeParams.join('&');\n    }\n    window.handleIFrameMessage = function(e) {\n      if (typeof e.data === 'object') { return; }\n      var args = e.data.split(\":\");\n      if (args.length > 2) { iframe = document.getElementById(\"JotFormIFrame-\" + args[(args.length - 1)]); } else { iframe = document.getElementById(\"JotFormIFrame\"); }\n      if (!iframe) { return; }\n      switch (args[0]) {\n        case \"scrollIntoView\":\n          iframe.scrollIntoView();\n          break;\n        case \"setHeight\":\n          iframe.style.height = args[1] + \"px\";\n          if (!isNaN(args[1]) && parseInt(iframe.style.minHeight) > parseInt(args[1])) {\n            iframe.style.minHeight = args[1] + \"px\";\n          }\n          break;\n        case \"collapseErrorPage\":\n          if (iframe.clientHeight > window.innerHeight) {\n            iframe.style.height = window.innerHeight + \"px\";\n          }\n          break;\n        case \"reloadPage\":\n          window.location.reload();\n          break;\n        case \"loadScript\":\n          if( !window.isPermitted(e.origin, ['jotform.com', 'jotform.pro']) ) { break; }\n          var src = args[1];\n          if (args.length > 3) {\n              src = args[1] + ':' + args[2];\n          }\n          var script = document.createElement('script');\n          script.src = src;\n          script.type = 'text\/javascript';\n          document.body.appendChild(script);\n          break;\n        case \"exitFullscreen\":\n          if      (window.document.exitFullscreen)        window.document.exitFullscreen();\n          else if (window.document.mozCancelFullScreen)   window.document.mozCancelFullScreen();\n          else if (window.document.mozCancelFullscreen)   window.document.mozCancelFullScreen();\n          else if (window.document.webkitExitFullscreen)  window.document.webkitExitFullscreen();\n          else if (window.document.msExitFullscreen)      window.document.msExitFullscreen();\n          break;\n      }\n      var isJotForm = (e.origin.indexOf(\"jotform\") > -1) ? true : false;\n      if(isJotForm && \"contentWindow\" in iframe && \"postMessage\" in iframe.contentWindow) {\n        var urls = {\"docurl\":encodeURIComponent(document.URL),\"referrer\":encodeURIComponent(document.referrer)};\n        iframe.contentWindow.postMessage(JSON.stringify({\"type\":\"urls\",\"value\":urls}), \"*\");\n      }\n    };\n    window.isPermitted = function(originUrl, whitelisted_domains) {\n      var url = document.createElement('a');\n      url.href = originUrl;\n      var hostname = url.hostname;\n      var result = false;\n      if( typeof hostname !== 'undefined' ) {\n        whitelisted_domains.forEach(function(element) {\n            if( hostname.slice((-1 * element.length - 1)) === '.'.concat(element) ||  hostname === element ) {\n                result = true;\n            }\n        });\n        return result;\n      }\n    };\n    if (window.addEventListener) {\n      window.addEventListener(\"message\", handleIFrameMessage, false);\n    } else if (window.attachEvent) {\n      window.attachEvent(\"onmessage\", handleIFrameMessage);\n    }\n    <\/script>\n","protected":false},"excerpt":{"rendered":"<p>1b) Our expert co-faculty are Tzu-Fei Wang MD @TzufeiWang, #thrombosis &amp; benign #shematologist from @OttawaHospital and founding @onc_ce faculty Alok Khorana MD @aakonc, Hardis Endowed Chair, Prof Med, Vice Chair Taussig Cancer Inst, Dir GI Cancers, @ClevelandClinic pic.twitter.com\/jKzhDBw1Ly &mdash; @onc_ce (@onc_ce) September 25, 2023 3) Let&#39;s start with the basics. Patients with #cancer have a [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","_mi_skip_tracking":false,"footnotes":""},"categories":[35],"tags":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1179"}],"collection":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/comments?post=1179"}],"version-history":[{"count":2,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1179\/revisions"}],"predecessor-version":[{"id":1182,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1179\/revisions\/1182"}],"wp:attachment":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/media?parent=1179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/categories?post=1179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/tags?post=1179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}